251 related articles for article (PubMed ID: 24707139)
1. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
Dhaneshwar SS
World J Gastroenterol; 2014 Apr; 20(13):3564-71. PubMed ID: 24707139
[TBL] [Abstract][Full Text] [Related]
2. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
3. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
Edmond LM; Hopkins MJ; Magee EA; Cummings JH
Inflamm Bowel Dis; 2003 Jan; 9(1):10-7. PubMed ID: 12656132
[TBL] [Abstract][Full Text] [Related]
4. Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach.
Suneela D; Gaurav V; Himanshu R
Inflamm Allergy Drug Targets; 2013 Oct; 12(5):328-40. PubMed ID: 24001333
[TBL] [Abstract][Full Text] [Related]
5. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
Mahmud N; Weir DG; Kelleher D
Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
7. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
Baker DE
Rev Gastroenterol Disord; 2005; 5(3):135-41. PubMed ID: 16127348
[TBL] [Abstract][Full Text] [Related]
8. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Baker DE; Kane S
Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
[TBL] [Abstract][Full Text] [Related]
10. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
11. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
12. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
13. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.
Brzezinski A; Rankin GB; Seidner DL; Lashner BA
Cleve Clin J Med; 1995; 62(5):317-23. PubMed ID: 7586488
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.
Simmonds NJ; Millar AD; Blake DR; Rampton DS
Aliment Pharmacol Ther; 1999 Mar; 13(3):363-72. PubMed ID: 10102970
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Sawarkar SP; Deshpande SG; Bajaj AN; Nikam VS
AAPS PharmSciTech; 2015 Dec; 16(6):1445-54. PubMed ID: 26017284
[TBL] [Abstract][Full Text] [Related]
16. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome.
McCoubrey LE; Seegobin N; Sangfuang N; Moens F; Duyvejonck H; Declerck E; Dierick A; Marzorati M; Basit AW
J Control Release; 2024 May; 369():630-641. PubMed ID: 38599548
[TBL] [Abstract][Full Text] [Related]
17. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
18. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L; Rathi B; Kadam SS
Eur J Med Chem; 2009 Oct; 44(10):3922-9. PubMed ID: 19442419
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
Van Gossum A
Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
